Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 8/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PARG | Q86W56 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414706 | 1.00 | NPC1 (0.41) | NPC1IDO1TDO2IRAK4LPL | |
| SCHEMBL27153282 | 0.82 | NPC1 (0.39) | NPC1IDO1TDO2IRAK4LPL | |
| SCHEMBL25346913 | 0.81 | IRAK4 (0.36) | NPC1IDO1TDO2IRAK4LPL | |
| SCHEMBL29513926 | 0.81 | IRAK4 (0.36) | NPC1IDO1TDO2IRAK4LPL | |
| SCHEMBL18189926 | 0.79 | NPC1 (0.37) | NPC1IRAK4LPLLIPGCA1 | |
| SCHEMBL22632582 | 0.78 | NPC1 (0.46) | NPC1 | |
| SCHEMBL26919614 | 0.78 | IRAK4 (0.38) | NPC1IDO1TDO2IRAK4LPL | |
| SCHEMBL29835702 | 0.78 | IRAK4 (0.38) | NPC1IDO1TDO2IRAK4LPL | |
| SCHEMBL20604761 | 0.78 | LPL (0.35) | NPC1IRAK4LPLLIPGCA1 | |
| SCHEMBL31387262 | 0.77 | IRAK4 (0.41) | IRAK4LPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114096531-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020227549-A1 | MODULATORS OF THR-β AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | NPC1 2683/4885IDO1 1971/4885TDO2 1199/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | NPC1 3125/4885IDO1 1533/4885TDO2 1070/4885 |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | NPC1 2683/4885IDO1 1971/4885TDO2 1199/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | NPC1 2374/4885IDO1 2168/4885TDO2 1308/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | NPC1 2374/4885IDO1 2168/4885TDO2 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.